Although several studies evaluating targeted therapies (BRAF and/or MEK inhibitors) and immunotherapies (anti–programmed cell death protein 1 [PD‐1] and/or anti‐cytotoxic T‐lymphocyte–associated protein 4 [CTLA‐4] therapies) have recently demonstrated clinical activity in patients with melanoma with CNS metastases,11, 12, 13, 14 information about elderly patients remains limited. Here, BRAF is linked to melanoma.